Dataset Information

Combinatory shotgun proteomics and shotgun eicosadomics study of platelets activated by calcium mobilization - secreted proteins of platelets stimulated for 3h with ionomycin

ABSTRACT: Platelets are involved in relevant physiological and pathophysiological processes such as hemostasis and tumor progression. These anucleate blood particles exert their functions essentially by releasing effector molecules such as proteins from intracellular granules and by generating and secreting specific lipids. In order to contribute to a systematic proteomics and eicosadomics analysis of platelets activated by calcium mobilization, we have investigated proteins and eicosanoids in lysates and secretomes of platelets activated with ionomycin. To this end, self-established shotgun proteomics and shotgun lipidomics platforms were used. Applying an FDR of less than 0.01 at both, peptide and protein level, a total of 2543 protein groups was identified. Several regulatory effects concerning proteins were determined, including protein secretion, degradation, as well as protein synthesis. Incorporation of 35S-methionine in platelet proteins determined by 2D-PAGE confirmed de-novo protein synthesis. Moreover, we were able to determine a complex set of eicosanoids synthesized by activated platelets, including 15S-HETE, prostaglandin E2 and pro-survival factors such as 12-HETE, as well as eicosanoids previously undescribed to have platelet functions, such as 9-HETE and 11-HETE. Proteomics data complemented the findings from lipidomics experiments and supported the generation of a map indicating pathways leading to eicosanoid production in platelets upon calcium mobilization.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Platelet, Platelet

SUBMITTER: Christopher Gerner

LAB HEAD: Christopher Gerner

PROVIDER: PXD005054 | Pride | 2022-03-01

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Platelets_secretome_3h_1_1.mgf	Mgf
	Platelets_secretome_3h_1_1.mzid.gz	Mzid
	Platelets_secretome_3h_1_1.pride.mgf.gz	Mgf
	Platelets_secretome_3h_1_1.pride.mztab.gz	Mztab
	Platelets_secretome_3h_1_1.raw	Raw

Items per page:

1 - 5 of 40

Publications

An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.

Meier Samuel M SM Kreutz Dominique D Winter Lilli L Klose Matthias H M MHM Cseh Klaudia K Weiss Tamara T Bileck Andrea A Alte Beatrix B Mader Johanna C JC Jana Samir S Chatterjee Annesha A Bhattacharyya Arindam A Hejl Michaela M Jakupec Michael A MA Heffeter Petra P Berger Walter W Hartinger Christian G CG Keppler Bernhard K BK Wiche Gerhard G Gerner Christopher C

Angewandte Chemie (International ed. in English) 20170526 28

Organometallic metal(arene) anticancer agents require ligand exchange for their anticancer activity and this is generally believed to confer low selectivity for potential cellular targets. However, using an integrated proteomics-based target-response profiling approach as a potent hypothesis-generating procedure, we found an unexpected target selectivity of a ruthenium(arene) pyridinecarbothioamide (plecstatin) for plectin, a scaffold protein and cytolinker, which was validated in a plectin knoc ...[more]

PMID: 28547791

Similar Datasets

Project description:Coronary artery disease (CAD) is the leading cause of human morbidity and mortality worldwide, underscoring the need to improve diagnostic strategies. Platelets play a major role, not only in the process of acute thrombosis during plaque rupture, but also in the formation of atherosclerosis itself. MicroRNAs are endogenous small non-coding RNAs that control gene expression and are expressed in a tissue and disease-specific manner. Therefore they have been proposed to be useful biomarkers. The aim of this study was to investigate whether differences in miRNA expression levels in platelets can be found (i) between patients with premature CAD and healthy controls and (ii) within healthy controls after and before aspirin and statin administration. In this case-control study we measured expression levels of platelet miRNAs using microarrays from 40 male patients with premature CAD and 40 age- and sex-matched healthy controls. Premature CAD was defined as a cardiac event before the age of 51 years. The patients were selected from the outpatient clinic of the Academic Medical Center (AMC) of Amsterdam, which is specialised in premature CAD. The control cohort was composed of 40 healthy Caucasian male volunteers, who were recruited by advertisement and who were matched with the cases for age and smoking habits. Individuals of this control cohort did not have a history of CVD, nor did they have a positive family history of CVD and they were not allowed to use any medication. Patients and controls were excluded when they suffered from diabetes. Most CAD patients use aspirin and statins as secondary prevention. The influence of these drugs on miRNA profiles is unknown. To assess the possible influence of medication on miRNA expression and to control for medication as confounding factor, we asked 27 volunteers in our control cohort to also use these drugs. We administered simvastatin 40 mg, once daily, for 6 weeks and during the last two weeks we added 100mg of acetyl salicylic acid, once daily. Blood samples including isolated platelets were collected at baseline in the absence of aspirin and statins and after six weeks of medication use. We also assessed platelet function using the Multiplate® Analyzer (Roche) in the absence of aspirin and statin use. In short, 300 µl whole blood was diluted with 300 µl 0.9% saline and stirred for 3 minutes at 37 ºC. Adenosine diphosphate (ADP) was added in a final concentration of 2.5 ?mol/L to initiate platelet aggregation. Aggregation was measured for 6 minutes and was reported in arbitrary aggregation units plotted against time. Also, the area under the aggregation curve (AUC) was measured. All samples were measured in the absence and presence of 200 ?mol/L indomethacin (20 min incubation with blood) to mimic the effect of aspirin use. We calculated the percentage reduction in AUC after incubation with indomethacin as an in vitro measure of the effect of aspirin use on whole blood platelet aggregation.

Project description:Fibroblasts have only recently been identified as important effector cells in inflammation. In this study, human dermal fibroblasts were inflammatory stimulated with interleukin-1beta and comprehensively analysed with respect to proteins, eicosanoids and metabolites. For eicosadomics, we have established a data-dependent shotgun analysis method capable of identifying inflammation-regulated lipids of yet unknown function. Several classical inflammatory agonists were found induced, including PGA2, PGB2, PGE2 and TXB2, but also modulators such as PGA3 and PGE3, while 8-HETE and several HODE family members remained unaffected. Using targeted metabolomics, several acylcarnithins, phosphatitylcholins and sphingomyelins were found significantly downregulated. Proteome profiling with orbitrap-MS demonstrated the strong induction of several chemokines, metalloproteinases and other effector molecules. Treatment of stimulated fibroblasts with dexamethasone almost completely abrogated the formation of all inflammation-induced eicosanoids and restored levels of acylcarnithins back to normal. As expected, the secretion of IL-6, MMP1, MMP3, CXCL2 and CXCL3 was strongly down-regulated. However, instead of counter-regulating, dexamethasone further enhanced consequences of inflammatory stimulation with respect to CXCL1, CXCL6, complement C3 as well as sphingomyelins. Shotgun secretome data were confirmed by targeted analysis with triple-quadrupol-MS. These molecules have been described to be involved in chronic inflammation. In peripheral blood mononuclear cells, actually dexamethasone successfully downregulated the formation of all detectable inflammation mediators. The present data suggest that successful pharmacological abrogation of the formation of lipid inflammatory mediators in fibroblasts may not suffice to suppress the release of several other powerful inflammatory mediators which we thus understand to be capable of establishing chronic inflammation states.